Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients

Journal of Pharmaceutical and Biomedical Analysis

Volumn 90, Issue , 2014, Pages 119-126

  Agnesod, Danilo ^a   De Nicolò, Amedeo ^a   Simiele, Marco ^a   Mohamed Abdi, Adnan ^a   Boglione, Lucio ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

HCV; Intracellular; PBMC; Phosphorylated drugs; Ribavirin

Indexed keywords

ACID PHOSPHATASE; ALPHA INTERFERON; DRUG METABOLITE; RIBAVIRIN; URIDINE;

ACCURACY; ANTIVIRAL THERAPY; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

HCV; INTRACELLULAR; PBMC; PHOSPHORYLATED DRUGS; RIBAVIRIN;

ANTIVIRAL AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; HEPATITIS C; HUMANS; LEAST-SQUARES ANALYSIS; LEUKOCYTES, MONONUCLEAR; PHOSPHORYLATION; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; TANDEM MASS SPECTROMETRY;

EID: 84890874297     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.11.027     Document Type: Article

References (53)

1. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., Bronowicki J.P., Bourliere M., Gharakhanian S., Bengtsson L., McNair L., George S., Kieffer T., Kwong A., Kauffman R.S., Alam J., Pawlotsky J.M., Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360:1839-1850.
2. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., Davis M.N., Galati J.S., Gordon S.C., Ravendhran N., Rossaro L., Anderson F.H., Jacobson I.M., Rubin R., Koury K., Pedicone L.D., Brass C.A., Chaudhri E., Albrecht J.K. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
3. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-S244.
4. D'Avolio A., Ciancio A., Siccardi M., Baietto L., Simiele M., Cariti G., Calcagno A., Smedile A., Cusato J., Bonora S., Rizzetto M., Di Perri G. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology 2011, 54:2278-2279.
5. D'Avolio A., Ciancio A., Siccardi M., Smedile A., Baietto L., Simiele M., Marucco D.A., Cariti G., Calcagno A., de Requena D.G., Sciandra M., Cusato J., Troshina G., Bonora S., Rizzetto M., Di Perri G. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Ther. Drug Monit. 2012, 34:165-170.
6. D'Avolio A., Ciancio A., Siccardi M., Smedile A., Simiele M., Cusato J., Baietto L., Marucco D.A., Cariti G., Calcagno A., de Requena D.G., Sciandra M., Troshina G., Caviglia G.P., Bonora S., Rizzetto M., Di Perri G. Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther. Drug Monit. 2012, 34:722-728.
7. D'Avolio A., De Nicolo A., Cusato J., Ciancio A., Boglione L., Strona S., Cariti G., Troshina G., Caviglia G.P., Smedile A., Rizzetto M., Di Perri G. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antivir. Res. 2013, 100:114-119.
8. De Nicolò A., Cusato J., Boglione L., Ciancio A., Smedile A., Agnesod D., Cariti G., Rizzetto M., Di Perri G., D'Avolio A. P_21 early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population. Rev. Antivir. Ther. Infect. Dis. 2013, 3:51.
9. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
10. Aguilar Marucco D., Gonzalez de Requena D., Bonora S., Tettoni C., Bonasso M., De Blasi T., D'Avolio A., Sciandra M., Siccardi M., Baietto L., Trentini L., Sinicco A., Cariti G., Di Perri G. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J. Antimicrob. Chemother. 2008, 61:919-924.
11. D'Avolio A., Cusato J., Calcagno A., Di Perri G. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?. J. Hepatol. 2013, 59:633-634.
12. Canta F., Marrone R., Bonora S., D'Avolio A., Sciandra M., Sinicco A., De Rosa F.G., Di Perri G. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J. Antimicrob. Chemother. 2005, 55:280-281.
13. D'Avolio A., Ciancio A., Siccardi M., Smedile A., Simiele M., Cusato J., Baietto L., Marucco D.A., Cariti G., Calcagno A., Gonzalez de Requena D., Sciandra M., Troshina G., Caviglia G.P., Bonora S., Rizzetto M., Di Perri G. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther. Drug Monit. 2012, 34:722-728.
14. D'Avolio A., Simiele M., De Francia S., Ariaudo A., Baietto L., Cusato J., Fava C., Saglio G., Di Carlo F., Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J. Pharm. Biomed. Anal. 2011, 59:109-116.
15. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Oddone V., Stefani F.R., Agati S., Cusato J., Bonora S., Di Perri G. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J. Pharm. Biomed. Anal. 2010, 54:779-788.
16. Simiele M., D'Avolio A., Baietto L., Siccardi M., Sciandra M., Agati S., Cusato J., Bonora S., Di Perri G. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 2011, 55:2976-2978.
17. Dominguez S., Ghosn J., Cassard B., Melica G., Poizot-Martin I., Solas C., Lascaux A.S., Bouvier-Alias M., Katlama C., Levy Y., Peytavin G. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. J. Antimicrob. Chemother. 2012, 67:1449-1452.
18. Kubota R., Komiyama T., Kumagai N., Kimijima M., Mitsuki K., Uetake J., Kaneko F., Tsunematsu S., Tsuchimoto K. Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection. Hepat. Res. Treat. 2010, 2010:495928.
19. Hammond K., Jimmerson L., MacBrayne C., Ray M., Bushman L., Burton J., Baouchi-Mokrane F., Everson G., Anderson P., Kiser J. PP_02 increased plasma and intracellular ribavirin concentrations associated with telaprevir use. Rev. Antiv. Ther. Infect. Dis. 2013, 3:26.
20. Boglione L., De Nicolò A., Cusato J., Cariti G., Perri G., D'Avolio A. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J. Viral Hepat. 2013, 10.1111/jvh.12170.
21. Caviglia G., D'Avolio A., Ciancio A., De Nicolò A., Boglione L., Abate M., Rosso C., Smedile A., Cariti G., Cusato J. F-33 early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy. Dig. Liver Dis. 2012, 44:S42.
22. D'Avolio A., De Nicolo A., Simiele M., Turini S., Agnesod D., Boglione L., Cusato J., Baietto L., Cariti G., Calcagno A., Sciandra M., Di Perri G., Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J. Pharm. Biomed. Anal. 2012, 66:376-380.
23. FDA Guidance for Industry: Bioanalytical Method Validation http://fda.gov/cder/guidance/4252fnl.pdf.
24. Danso D., Langman L.J., Snozek C.L. LC-MS/MS quantitation of ribavirin in serum and identification of endogenous isobaric interferences. Clin. Chim. Acta 2011, 412:2332-2335.
25. Melendez M., Rosario O., Zayas B., Rodriguez J.F. HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells. J. Pharm. Biomed. Anal. 2009, 49:1233-1240.
26. Homma M., Jayewardene A.L., Gambertoglio J., Aweeka F. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob. Agents Chemother. 1999, 43:2716-2719.
27. Homma M., Matsuzaki Y., Inoue Y., Shibata M., Mitamura K., Tanaka N., Kohda Y. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin. Gastroenterol. Hepatol. 2004, 2:337-339.
28. Inoue Y., Homma M., Matsuzaki Y., Shibata M., Matsumura T., Ito T., Mitamura K., Tanaka N., Kohda Y. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob. Agents Chemother. 2004, 48:3813-3816.
29. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005, 38:328-334.
30. Marquet P., Sauvage F.L., Loustaud-Ratti V., Babany G., Rousseau A., Lachatre G. Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. Ther. Drug Monit. 2007, 32:237-241.
31. Loregian A., Scarpa M.C., Pagni S., Parisi S.G., Palu G. Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 856:358-364.
32. D'Avolio A., Ibanez A., Sciandra M., Siccardi M., de Requena D.G., Bonora S., Di Perri G. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 835:127-130.
33. Tempestilli M., Milano E., D'Offizi G., Montalbano M., D'Avolio A., Gasperi T., Narciso P., Ascenzi P., Pucillo L.P. Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV. IUBMB Life 2013, 65:800-805.
34. D'Avolio A., De Nicolo A., Agnesod D., Simiele M., Mohamed Abdi A., Dilly Penchala S., Boglione L., Cariti G., Di Perri G. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. J. Pharm. Biomed. Anal. 2013, 78-79:217-223.
35. Farnik H., El-Duweik J., Welsch C., Sarrazin C., Lotsch J., Zeuzem S., Geisslinger G., Schmidt H. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:4001-4006.
36. Shen J.X., Merka E.A., Dreyer D.P., Clement R.P., Hayes R.N. Stereoselective quantitation of a serine protease inhibitor using LC-MS/MS at elevated column temperature. J. Sep. Sci. 2008, 31:242-254.
37. Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob. Agents Chemother. 2013, 57:3147-3158.
38. Penchala S.D., Tjia J., El Sherif O., Back D.J., Khoo S.H., Else L.J. Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 932:100-110.
39. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
40. De Franceschi L., Fattovich G., Turrini F., Ayi K., Brugnara C., Manzato F., Noventa F., Stanzial A.M., Solero P., Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000, 31:997-1004.
41. Karino Y., Ozeki I., Hige S., Kimura M., Arakawa T., Nakajima T., Kuwata Y., Sato T., Ohmura T., Toyota J. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J. Viral Hepat. 2013, 10.1111/jvh.12162.
42. Morello J., Rodriguez-Novoa S., Cantillano A.L., Gonzalez-Pardo G., Jimenez I., Soriano V. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther. Drug Monit. 2007, 29:802-806.
43. Shou W.Z., Bu H.Z., Addison T., Jiang X., Naidong W. Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum. J. Pharm. Biomed. Anal. 2002, 29:83-94.
44. Hitomi Y., Cirulli E.T., Fellay J., McHutchison J.G., Thompson A.J., Gumbs C.E., Shianna K.V., Urban T.J., Goldstein D.B. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011, 140:1314-1321.
45. Yeh L.T., Nguyen M., Dadgostari S., Bu W., Lin C.C. LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells. J. Pharm. Biomed. Anal. 2007, 43:1057-1064.
46. Yeh L.T., Nguyen M., Lin C.C. A sensitive and specific method for the determination of total ribavirin in human red blood cells by liquid chromatography-tandem mass spectrometry. J. Chromatogr. Sci. 2003, 41:255-260.
47. Bushman L.R., Kiser J.J., Rower J.E., Klein B., Zheng J.H., Ray M.L., Anderson P.L. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J. Pharm. Biomed. Anal. 2011, 56:390-401.
48. Kromdijk W., Pereira S.A., Rosing H., Mulder J.W., Beijnen J.H., Huitema A.D. Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 919-920:43-51.
49. Guo S., Duan J.A., Qian D., Wang H., Tang Y., Qian Y., Wu D., Su S., Shang E. Hydrophilic interaction ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry for determination of nucleotides, nucleosides and nucleobases in Ziziphus plants. J. Chromatogr. A 2013, 1301:147-155.
50. Dervieux T., Meyer G., Barham R., Matsutani M., Barry M., Boulieu R., Neri B., Seidman E. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin. Chem. 2005, 51:2074-2084.
51. Zhao Y., Liu G., Liu Y., Yuan L., Hawthorne D., Shen J.X., Guha M., Aubry A. Improved ruggedness of an ion-pairing liquid chromatography/tandem mass spectrometry assay for the quantitative analysis of the triphosphate metabolite of a nucleoside reverse transcriptase inhibitor in peripheral blood mononuclear cells. Rapid Commun. Mass Spectrom. 2013, 27:481-488.
52. D'Avolio A., Simiele M., Calcagno A., Siccardi M., Larovere G., Agati S., Baietto L., Cusato J., Tettoni M., Sciandra M., Trentini L., Di Perri G., Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J. Antimicrob. Chemother. 2012, 68:907-910.
53. Gao W.Y., Cara A., Gallo R.C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:8925-8928.